Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 20, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast Cancer at ESMO)
TOKYO, October 20, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on October 18, including the latest data of giredestrant for estrogen receptor (ER)- positive breast cancer, presented at the European Society for Medical Oncology Congress (ESMO) 2025.
Please refer to the link below for details of the press release:
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp